

Applied DNA Sciences Begins a Testing Program for Novel Anti-Sepsis Agents for Accuthera, Inc.

STONY BROOK, N.Y., July 27 /PRNewswire-FirstCall/ -- Applied DNA Sciences, Inc. (OTC Bulletin Board: APDN), a DNA security solutions company, today announced that it has agreed to a commercial agreement providing for APDN to manage a portion of a testing program for Accuthera, Inc, focusing on evaluation of a novel series of proteinase inhibitors. The Accuthera program is being conducted in conjunction with an ongoing major initiative of the Rocky Mountain Regional Center of Excellence in Fort Collins, CO, under the sponsorship of the National Institute of Allergy and Infectious Diseases.

Accuthera is pursuing the development of a novel series of low molecular weight compounds for controlling the systemic inflammation associated with sepsis. This condition is associated with high morbidity and mortality. Previous efforts to develop successful targeted therapeutic strategies for sepsis have been limited by incomplete understanding of the requirements for optimal drug design as well as inadequate detection of early warning signs of escalating systemic inflammatory responses in septic patients. If these warning signs could be recognized with greater reliability, the effectiveness of therapeutic interventions could be considerably increased. Accuthera's approach makes use of rigorous evaluation of biomarkers under conditions amenable to monitoring in the hospital bedside setting as well as comprehensive evaluation of the functional efficacy of its candidate proteinase inhibitors under conditions replicating the onset of the systemic inflammatory response.

Dr. John C. Cheronis, M.D., Ph.D, CEO of Accuthera Inc., stated, "We are very pleased to develop a collaboration with Applied DNA Sciences. The results from the tests to be funded by us and managed by Applied DNA will help us screen candidate drugs for efficacy using a number of in vitro assays."

Dr. James A. Hayward, Ph.D., Sc.D., CEO of APDN, stated, "The current management team at Applied has extensive previous experience with the development and commercialization of proteinase inhibitors. In addition, our decision to join this partnership is also designed to facilitate collaboration between Accuthera and investigators at Stony Brook University. APDN is seeking to increase its presence in the pharma and biotech industries, where the scientific foundations of APDN's platforms can be applied to prevent the production and distribution of counterfeit drugs."

About Applied DNA Sciences, Inc.

Applied DNA Sciences, Inc. (APDN) develops proprietary DNA-embedded security solutions that use plant DNA to verify authenticity and protect corporate and government agencies from counterfeiting, fraud, piracy, product diversion, identity theft and unauthorized intrusion into physical plant and databases. Our common stock is registered under Section 12(g) of the Securities Exchange Act of 1934 and is listed on the Over-The-Counter Bulletin Board under the symbol "APDN". Contact: MeiLin Wan, Applied DNA Sciences, Inc., 25 Health Sciences Drive, Stony Brook, New York 11790; Tel: 631-444-6370; Fax: 631-444.8848 <http://www.ADNAS.com>.

The statements made by Applied DNA Sciences, Inc. may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe the Company's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA Sciences, Inc. Actual results could differ materially from those projected due to changes in interest rates, market competition, changes in the local and national economies, and various other factors detailed from time to time in Applied DNA Sciences' SEC reports and filings, including our Annual Report on Form 10-KSB, filed on January 12, 2006, our subsequent Quarterly Reports on Form 10-QSB, and our Current Reports on Form 8-K. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.

